Rating Rationale
March 29, 2018 | Mumbai
Allengers Medical Systems Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.63 Crore
Long Term Rating CRISIL A-/Stable (Reaffirmed)
Short Term Rating CRISIL A2+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL A-/Stable/CRISIL A2+' ratings on bank facilities of Allengers Medical Systems Limited (AMSL).
 
CRISIL's ratings continue to reflect AMSL's strong market position in the domestic X-ray-based medical equipment industry, established marketing and distribution network, diversity in product range, geographic reach and clientele, and the healthy financial risk profile. These rating strengths are partially offset by large working capital requirement, and exposure to risks related to intense competition and volatility in foreign exchange (forex) rates.

Key Rating Drivers & Detailed Description
Strengths
* Strong market position in the domestic X-ray-based medical equipment industry, backed by established marketing and distribution network: Backed by a diverse marketing and sales network (comprising a 100-plus trained salesforce and 150 service engineers at 45 offices across India), and a proven track record of delivering quality products, AMSL has gained sizeable market share, and established the brand, Allengers, at various price points, with a strong recall in the medical equipment industry. Growing penetration has helped AMSL cater to demand even from small clinics and standalone hospitals, and achieve healthy revenue growth in the domestic market. Performance has also been driven by the increasing demand for quality healthcare services and huge investment in the medical sector over the five years ended March 31, 2017.
 
* Diversified product range, geographic reach and customer base: AMSL manufactures eight major forms of medical equipment, with over 30 variants in segments such as radiology, cardiology, urology, neurology, orthopaedics, and gastroenterology, and caters to both, price-sensitive, and feature-driven customers. Products such as C-Arms and high frequency X-rays were launched in a manner that high-end variants were supplied to large hospitals/institutes, and medium to lower-end versions were offered to local doctors/medical practitioners.
 
* Healthy financial risk profile: Financial risk profile is marked by a healthy networth and gearing of around Rs 111 crore and 0.06 time as on March 31, 2017, mainly aided by low term debt, comprising vehicle loans (Rs 1.12 crore) and healthy accretion to reserves. Gearing has remained low over the last 2 years ended on March 2017. Debt protection metrics were strong, driven by low outstanding debt and healthy cash accrual. Interest coverage and cash accrual to total debt ratios has remained strong at 9.58 times and 2.78 times, respectively, in fiscal 2017.
 
These strengths are partially offset by AMSL's following weaknesses:

* Working capital-intensive operations: Gross current assets stood at 169 days as on March 31, 2017, primarily led by large receivables and moderate inventory. Receivables outstanding for over six months mainly stem from the government sector and large orders from private customers. Raw material accounted for around 70% of the inventory (86 days as on March 31, 2017). In spite of limited trade credit support (60 days) from suppliers, overall reliance on short-term debt has declined due to improvement in working capital management and net cash accrual. Working capital management will remain a key rating sensitivity factor going forward.
 
* Intense competition from established players and volatility in forex rates: Despite being the largest player in the X-ray segment in India, AMSL faces stiff competition from reputed brands such as Siemens Healthcare, GE Healthcare, and Philips Healthcare, unorganised players, and cheap low-end equipment from China. Hence, to counter competition, AMSL has priced its products significantly lower than its competitors, and thus, faces pressure on profitability.
 
With nearly 30% of equipment being imported, and exports accounting for almost 14% of revenue in fiscal 2017, the company enjoys a partial hedge against forex exposure. It hedges only 10% of the overall exposure, and therefore, remains highly susceptible to fluctuations in forex rates.
Outlook: Stable

CRISIL believes AMSL will continue to benefit from its strong market position, established marketing and distribution network, and healthy financial risk profile. The outlook may be revised to 'Positive' if the company reports substantial growth in sales and profitability, better working capital management and financial risk profile remaining at current levels. The outlook may be revised to 'Negative' if the financial risk profile, particularly liquidity, weakens, most likely due to a decline in revenue and profitability, any large capital expenditure, or stretch in the working capital cycle.

About the Company

AMSL was established as a proprietorship concern of Mr Suresh Sharma, based in Chandigarh, in 1987. The firm was reconstituted as a closely held public limited company in 1997. The company manufactures various X-ray-based medical diagnostic and imaging equipment.

Key Financial Indicators (Standalone)
Particulars Unit 2017 2016
Revenue Rs crore 266 287
Profit after tax Rs crore 18 23
PAT margins % 6.9 8.1
Adjusted debt/adjusted networth Times 0.06 0.08
Interest coverage Times 13.9 20.7

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue Size
(Rs crore)
Rating assigned with outlook
NA Bank Guarantee NA NA NA 22.00 CRISIL A2+
NA Cash Credit NA NA NA 33.50 CRISIL A-/Stable
NA Letter of credit & Bank Guarantee NA NA NA 1.50 CRISIL A2+
NA Proposed Fund-Based Bank Limits Na NA NA 6.00 CRISIL A-/Stable
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Quantum Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  39.5  CRISIL A-/Stable    No Rating Change    No Rating Change  06-12-16  CRISIL A-/Stable    No Rating Change  CRISIL A-/Stable/ CRISIL A2+ 
Non Fund-based Bank Facilities  LT/ST  23.5  CRISIL A2+    No Rating Change    No Rating Change    No Rating Change    No Rating Change  CRISIL A2+ 
Table reflects instances where rating is changed or freshly assigned. 'No Rating Change' implies that there was no rating change under the release.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 22 CRISIL A2+ Bank Guarantee 22 CRISIL A2+
Cash Credit 33.5 CRISIL A-/Stable Cash Credit 33.5 CRISIL A-/Stable
Letter of credit & Bank Guarantee 1.5 CRISIL A2+ Letter of credit & Bank Guarantee 1.5 CRISIL A2+
Proposed Fund-Based Bank Limits 6 CRISIL A-/Stable Proposed Fund-Based Bank Limits 6 CRISIL A-/Stable
Total 63 -- Total 63 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings
The Rating Process
Understanding CRISILs Ratings and Rating Scales

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Jyoti Parmar
Media Relations
CRISIL Limited
D: +91 22 3342 1835
B: +91 22 3342 3000
 jyoti.parmar@crisil.com

Aditya Sarda
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
aditya.sarda@crisil.com


Rishabh Jain
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2192
rishabh.jain@crisil.com


Nilesh Agarwal
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 79 4024 4536
Nilesh.Agarwal1@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the “Company) you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit https://www.crisil.com/en/home/privacy-and-cookie-notice.html. You can view the Company’s Customer Privacy at https://www.spglobal.com/corporate-privacy-policy

Last updated: April 2016


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL